Bumetanide Injection

• • Bumetanide injection, Athenex, 0.25 mg/mL, 10 mL vial, 10 count, NDC 70860-0406-10
  • Bumetanide injection, Athenex, 0.25 mg/mL, 4 mL vial, 10 count, NDC 70860-0405-04
  • Bumetanide injection, Hikma, 0.25 mg/mL, 10 mL vial, 10 count, NDC 00641-6007-10
  • Bumetanide injection, Hikma, 0.25 mg/mL, 4 mL vial, 10 count, NDC 00641-6008-10
  • Bumetanide injection, Pfizer, 0.25 mg/mL, 10 mL vial, 10 count, NDC 00409-1412-10 - discontinued
  • Bumetanide injection, Pfizer, 0.25 mg/mL, 4 mL vial, 10 count, NDC 00409-1412-04 - discontinued

• • Athenex launched bumetanide injection in February 2022.
  • Hikma did not provide a reason for the shortage.
  • Pfizer has discontinued bumetanide injection in August 2022.

• • There is insufficient supply for usual ordering

Estimated Resupply Dates

• • Athenex has bumetanide 0.25 mg/mL 4 mL and vials on back order and the company estimates a release date of February 2023.
  • Hikma has bumetanide 0.25 mg/mL 4 mL and 10 mL vials on allocation.